Rupert W Major1, Chee Kay Cheung2, Laura J Gray3, Nigel J Brunskill2. 1. The John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom; and Departments of Health Sciences, and rm157@le.ac.uk. 2. Infection, Immunity, and Inflammation, University of Leicester, Leicester, United Kingdom The John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom; and. 3. Departments of Health Sciences, and.
Abstract
BACKGROUND AND OBJECTIVES: Multiple meta-analyses of lipid-lowering therapies for cardiovascular primary prevention in the general population have been performed. Other meta-analyses of lipid-lowering therapies in CKD have also been performed, but not for primary prevention. This meta-analysis assesses lipid-lowering therapies for cardiovascular primary prevention in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A systematic review and meta-analysis using a random-effects model was performed. MEDLINE was searched between January 2012 and September 2013 for new studies using predefined search criteria without language restrictions. A number of other sources including previously published meta-analyses were also reviewed. Inclusion criteria were randomized control trials of primary prevention with lipid-lowering therapy in non-end stage CKD. RESULTS: Six trials were identified, five including patients with stage 3 CKD only. These studies included 8834 participants and 32,846 person-years of follow-up. All trials were post hoc subgroup analyses of statins in the general population. Statins reduced the risk of cardiovascular disease (the prespecified primary outcome) by 41% in stages 1-3 CKD compared with placebo (pooled risk ratio, 0.59; 95% confidence interval [95% CI], 0.48 to 0.72). For the secondary outcomes, the risk ratios were 0.66 (95% CI, 0.49 to 0.88) for total mortality, 0.55 (95% CI, 0.42 to 0.72) for coronary heart disease events, and 0.56 (95% CI, 0.28 to 1.13) for stroke. In study participants with stage 3 CKD specifically, the results were similar. CONCLUSIONS: This meta-analysis suggests that the use of statins in CKD for primary prevention of cardiovascular disease is effective. These findings are consistent with recent guidance for the use of statins in all patients with CKD.
BACKGROUND AND OBJECTIVES: Multiple meta-analyses of lipid-lowering therapies for cardiovascular primary prevention in the general population have been performed. Other meta-analyses of lipid-lowering therapies in CKD have also been performed, but not for primary prevention. This meta-analysis assesses lipid-lowering therapies for cardiovascular primary prevention in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A systematic review and meta-analysis using a random-effects model was performed. MEDLINE was searched between January 2012 and September 2013 for new studies using predefined search criteria without language restrictions. A number of other sources including previously published meta-analyses were also reviewed. Inclusion criteria were randomized control trials of primary prevention with lipid-lowering therapy in non-end stage CKD. RESULTS: Six trials were identified, five including patients with stage 3 CKD only. These studies included 8834 participants and 32,846 person-years of follow-up. All trials were post hoc subgroup analyses of statins in the general population. Statins reduced the risk of cardiovascular disease (the prespecified primary outcome) by 41% in stages 1-3 CKD compared with placebo (pooled risk ratio, 0.59; 95% confidence interval [95% CI], 0.48 to 0.72). For the secondary outcomes, the risk ratios were 0.66 (95% CI, 0.49 to 0.88) for total mortality, 0.55 (95% CI, 0.42 to 0.72) for coronary heart disease events, and 0.56 (95% CI, 0.28 to 1.13) for stroke. In study participants with stage 3 CKD specifically, the results were similar. CONCLUSIONS: This meta-analysis suggests that the use of statins in CKD for primary prevention of cardiovascular disease is effective. These findings are consistent with recent guidance for the use of statins in all patients with CKD.
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Marcello Tonelli; Anita Lloyd; Fiona Clement; Jon Conly; Don Husereau; Brenda Hemmelgarn; Scott Klarenbach; Finlay A McAlister; Natasha Wiebe; Braden Manns Journal: CMAJ Date: 2011-10-11 Impact factor: 8.262
Authors: Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim Journal: Cochrane Database Syst Rev Date: 2013-01-31
Authors: Ashish Upadhyay; Amy Earley; Jenny L Lamont; Shana Haynes; Christoph Wanner; Ethan M Balk Journal: Ann Intern Med Date: 2012-08-21 Impact factor: 25.391
Authors: Kevin F Erickson; Sohan Japa; Douglas K Owens; Glenn M Chertow; Alan M Garber; Jeremy D Goldhaber-Fiebert Journal: J Am Coll Cardiol Date: 2013-03-26 Impact factor: 24.094
Authors: R Andrew Moore; David J Gavaghan; Jayne E Edwards; Phillip Wiffen; Henry J McQuay Journal: BMC Med Res Methodol Date: 2002-01-25 Impact factor: 4.615
Authors: Ankush Jamthikar; Deep Gupta; Luca Saba; Narendra N Khanna; Tadashi Araki; Klaudija Viskovic; Sophie Mavrogeni; John R Laird; Gyan Pareek; Martin Miner; Petros P Sfikakis; Athanasios Protogerou; Vijay Viswanathan; Aditya Sharma; Andrew Nicolaides; George D Kitas; Jasjit S Suri Journal: Cardiovasc Diagn Ther Date: 2020-08
Authors: Ellen K Hoogeveen; Johanna M Geleijnse; Erik J Giltay; Sabita S Soedamah-Muthu; Janette de Goede; Linda M Oude Griep; Theo Stijnen; Daan Kromhout Journal: PLoS One Date: 2017-02-09 Impact factor: 3.240
Authors: Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth Journal: Am J Prev Cardiol Date: 2021-01-23
Authors: Emilio Rodrigo; Sara Pich; Isaac Subirana; Gema Fernandez-Fresnedo; Paloma Barreda; Carles Ferrer-Costa; Ángel Luis M de Francisco; Eduardo Salas; Roberto Elosua; Manuel Arias Journal: Clin Kidney J Date: 2017-06-22